Amphiregulin Releasing Alginate Hydrogel

This hydrogel can be injected into injured muscle, where it can gradually release AREG into the surrounding injured muscle to reduce inflammation and promote regeneration.

Technology

Peripheral Arterial Disease (PAD) affects more than 200 million people globally. PAD leads to ischemia, the narrowing of the arteries, which causes muscle damage & degeneration, impaired peripheral nerve function, and necrosis of the tissue. Current treatments primarily focus on restoring blood flow, but they fail to address the significant muscle damage. This gap in treatment leaves patients with chronic pain, loss of mobility, and a high risk of amputation. UD Researchers have developed an alginate hydrogel therapeutic platform that directly addresses this unmet need. The tunable hydrogel platform can provide sustained and controlled release of a potent growth factor called amphiregulin (AREG). AREG interacts with the EGFR receptor on cells and has been shown to activate regulatory T-cells, muscle cells, blood vessel cells, and nerve cells, to reduce inflammation and promote regeneration. By adjusting the degradation of the alginate polymer, the hydrogel releases AREG over time in a sustained and controlled release. This hydrogel can be injected into injured muscle, where it can gradually release AREG into the surrounding injured muscle to reduce inflammation and promote regeneration. Preliminary results from a mouse model of acute PAD have successfully demonstrated this hydrogel’s ability to promote regeneration in the muscle and nerve tissue. This technology may have utility in treating other pathologies and injuries where muscle and nerve regeneration is required. This localized delivery concentrates the regenerative factor exactly where it’s needed, maximizing its therapeutic effect while minimizing potential side effects.

Benefits

  • Local, sustained, and controlled release of AREG.
  • Minimally invasive.
  • Promote muscle and nerve regeneration.
  • Reduces tissue necrosis.
  • Actively decreases inflammation and the formation of scar tissue.
  • Adaptable, biocompatible platform.

Applications

This versatile platform has significant commercial potential across multiple high-value markets. Ideal partners include:

  • Medical Device companies specializing in stents, angioplasty balloons, and vascular grafts
  • Pharmaceutical and biotech firms with a focus on biologics, growth factors, tissue repair, and advanced wound healing.
  • Trauma & Orthopedic Surgery Companies providing solutions for acute trauma, sports medicine, and reconstructive surgery.

Additional info

Value Proposition: This technology offers a localized, sustained-release hydrogel therapy that protects muscle from death, reduces scarring, and promotes functional recovery after ischemic injury.